HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cosmetics ‘Are Not Risk-Free’; FDA Committed to Modernizing Regs – Commish Gottlieb

Executive Summary

FDA is committed to working with Congress to update cosmetics regulations and its related authorities, as “we have not been able to expand the scope of what we’re able to do commensurate with the expansion and the scope of this industry,” Commissioner Scott Gottlieb told House appropriators Feb. 26.

You may also be interested in...



Gottlieb Leaves FDA With Final Thought On What To Do About Cosmetics

Addressing for the last time the House Appropriations subcommittee with FDA oversight, Commissioner Scott Gottlieb shared his vision for sharpening cosmetics oversight in the absence of significant new resources.

PCPC: State Legislation, ‘Fake Science,' FDA’s Sunscreen Monograph Among Top 2019 Challenges

The Personal Care Products Council’s top execs identified key legislative, regulatory and public affairs challenges facing industry in 2019 during a Feb. 26 panel discussion at the group’s annual meeting in Palm Beach, Fla.

'Data Gaps' Keep 12 Ingredients Off FDA's Proposed OTC Sunscreen Monograph

FDA proposed final sunscreen monograph identifies zinc oxide and titanium dioxide as GRASE, two other ingredients as non-GRASE and 12 substances with data gaps, meaning firms must provide safety and effectiveness data or reformulate products that rely on inadequately supported UV filters. EWG says the proposal is “exactly the kind of signal that FDA should be providing for the sunscreen industry.”

Related Content

Topics

UsernamePublicRestriction

Register

RS148591

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel